1712-Estrogen-Driven Resistance in Cancer Therapy
This study uncovers a sex-biased resistance to antibody-drug conjugates in cancer therapies, showing that estrogen triggers a signaling switch in tumor cells that drives neutrophil extracellular trap (NET) formation. The researchers demonstrate that these NET structures physically shield tumor-cell-surface antigens, thereby restricting drug access and significantly diminishing treatment efficacy across multiple models. By identifying GPER1-dependent STING reprogramming and CXCL1-mediated neutrophil recruitment as the underlying mechanisms, the findings establish that pharmacologic NET…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.